Affinage

Showing RIOX2 — MINA is a alias.

RIOX2

Ribosomal oxygenase 2 · UniProt Q8IUF8

Length
465 aa
Mass
52.8 kDa
Annotated
2026-06-10
46 papers in source corpus 22 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RIOX2 (MINA53/mdig) is a JmjC-domain 2-oxoglutarate oxygenase that couples chromatin modification to cell proliferation, acting both as a histone-modification "eraser" and as a protein hydroxylase (PMID:19502796, PMID:36908702, PMID:39587091). As a demethylase it removes repressive H3K9me3 at target promoters and preferentially demethylates H3K36me3 in vitro, and it also functions as an arginine demethylase for histone H4R3me2a (PMID:19502796, PMID:31165872, PMID:39587091). Through H3K9me3 erasure it derepresses growth-promoting loci including rRNA genes, the H19 lncRNA, p21(CIP1/WAF1), CDC6, and OTX2, the last sustaining a self-reinforcing OTX2–Myc loop that drives hepatocyte proliferation during liver regeneration (PMID:19502796, PMID:23965803, PMID:28471446, PMID:32312832, PMID:37709738). Beyond histones, RIOX2 is an arginine demethylase for p53, removing R337me2a to reduce p53 stability and oligomerization and thereby suppress p53-dependent cell-cycle arrest and promote tumor growth (PMID:39864061). It is a histidine hydroxylase that catalyzes C-3 hydroxylation of a specific histidine in ribosomal protein Rpl27a (PMID:36908702). Consistent with these activities, RIOX2 is a direct c-Myc transcriptional target whose expression is required for proliferation, localizes constitutively to the nucleolar granular component and preribosomal particles, and modulates cell-cycle progression, EMT, replication, drug resistance, and Th17/Treg immune balance (PMID:12091391, PMID:15819408, PMID:25851349, PMID:30333481, PMID:29039479). Its catalytic loss broadly reshapes the epigenome — deletion raises global H3K9me3, H3K36me3, and DNA methylation, altering motility and invasion programs in cancer cells (PMID:30254753, PMID:36124233).

Mechanistic history

Synthesis pass · year-by-year structured walk · 22 steps
  1. 2002 High

    Establishing what drives RIOX2 expression and why it matters: defining it as a direct c-Myc effector linked the gene to proliferative control from the outset.

    Evidence ChIP, promoter-reporter, c-MycER/cycloheximide block, and RNAi with proliferation readout in cultured cells

    PMID:12091391

    Open questions at the time
    • Did not define the biochemical activity of the protein
    • Mechanism linking expression to proliferation unresolved
  2. 2005 High

    Localizing the protein answered where it acts: constitutive nucleolar/preribosomal residence tied RIOX2 to ribosome biogenesis and rRNA metabolism.

    Evidence Immunolocalization, fractionation, co-IP/MALDI-MS, and RNase A/actinomycin D/serum-starvation perturbations

    PMID:15819408

    Open questions at the time
    • Interactor identities not resolved to specific functional partners
    • No catalytic activity demonstrated
  3. 2009 Medium

    First assignment of a catalytic function: RIOX2 demethylates H3K9me3 at rRNA gene promoters to license Pol I transcription.

    Evidence Gain/loss-of-function with ChIP for H3K9me3 and Pol I plus rRNA assays

    PMID:19502796

    Open questions at the time
    • No in vitro reconstitution in this study
    • Direct vs indirect demethylation not separated
  4. 2013 Medium

    Confirmed direct H3K9me3 demethylase activity and extended it to an imprinted locus, showing catalysis is intrinsic to RIOX2.

    Evidence In vitro demethylation with immunoprecipitated mdig plus cellular ChIP at the H19 promoter

    PMID:23965803

    Open questions at the time
    • Immunoprecipitated (not purified recombinant) enzyme used
    • Substrate specificity versus other marks not addressed
  5. 2013 Medium

    Defined a physiological role in immunity: RIOX2 controls Th17/Treg balance and allergic airway responses in vivo.

    Evidence Mina53-knockout mice with allergen challenge, BAL differentials, cytokine ELISA, and airway hyperresponsiveness

    PMID:23748603

    Open questions at the time
    • Molecular target in T cells not identified
    • Catalytic dependence of the phenotype untested
  6. 2015 Medium

    Mapped the protein interactome, placing RIOX2 with DNA repair and chromatin factors.

    Evidence Reciprocal co-IP plus nanoESI-MS/MS in A549 and BEAS-2B cells (XRCC5, XRCC6, RBBP4, CBX8, PRMT5, TDRD)

    PMID:26293673

    Open questions at the time
    • Functional consequence of each interaction undefined
    • Direct vs complex-mediated binding not resolved
  7. 2015 Medium

    Connected RIOX2 to cell-cycle regulation through p27(KIP1), explaining its proliferative requirement.

    Evidence siRNA knockdown with proliferation/cell-cycle assays, p27 and phospho-p27 Western blots, and tumor-tissue correlation

    PMID:25851349

    Open questions at the time
    • Whether p27 regulation is epigenetic or indirect unclear
    • No catalytic-dead control
  8. 2016 Medium

    Identified signaling partners, showing RIOX2 binds c-Myc and JAK1 to amplify IL-6–JAK–STAT3 signaling.

    Evidence Co-IP, integrative genomics/proteomics, and siRNA knockdown with STAT3 phosphorylation readout in myeloma cells

    PMID:27833099

    Open questions at the time
    • Direct binding interface not mapped
    • Catalytic involvement in signaling untested
  9. 2017 Medium

    Extended the H3K9me3-demethylase paradigm to tumor-suppressor control via p21 in hepatocellular carcinoma.

    Evidence Gain/loss-of-function, ChIP for H3K9me3 at the p21 promoter, and xenograft model

    PMID:28471446

    Open questions at the time
    • Single-lab observation
    • Other p21-controlling inputs not excluded
  10. 2017 Medium

    Defined a context-dependent anti-EMT role through GSK-3β/β-catenin signaling in NSCLC.

    Evidence Overexpression/knockdown with invasion assays and Western blots for EMT markers and transcription factors

    PMID:29039479

    Open questions at the time
    • Link between catalytic activity and β-catenin signaling unestablished
    • Cell-line restricted
  11. 2018 Medium

    Provided structural/evolutionary framing and assigned histidine hydroxylase activity on Rpl27a, distinguishing RIOX2 catalysis from pure demethylation.

    Evidence Phylogenomics across 49 species, domain comparison, and immunofluorescence localization (human vs Hydra)

    PMID:29914368

    Open questions at the time
    • Hydroxylase activity inferred here, assayed directly later
    • Functional consequence of Rpl27a hydroxylation unknown
  12. 2018 Medium

    Showed catalytic loss reshapes the epigenome and metastatic behavior, casting RIOX2 as a suppressor of DNA/histone methylation in TNBC.

    Evidence Knockdown with global DNA-methylation, chromatin accessibility, H3K9me3 ChIP, and migration/invasion assays

    PMID:30254753

    Open questions at the time
    • Direct vs indirect effects on global methylation not separated
  13. 2018 Medium

    Linked RIOX2 to DNA replication licensing, explaining proliferation arrest upon loss.

    Evidence siRNA knockdown in glioblastoma with replication-initiation assays, CMG gene expression, DDR Western blots, and apoptosis flow cytometry

    PMID:30333481

    Open questions at the time
    • Whether CMG genes are direct chromatin targets untested
  14. 2019 High

    Established H3K36me3 as a preferred substrate in vitro and a druggable role in HIV-1 latency.

    Evidence CRISPR screen, RNAi, in vitro demethylation assay, LTR ChIP, latency reactivation, and JIB-04 inhibition

    PMID:31165872

    Open questions at the time
    • Relative cellular preference for H3K9me3 vs H3K36me3 not quantified
  15. 2019 Medium

    Connected RIOX2 to chemoresistance via WNT/β-catenin-driven ABC transporter expression.

    Evidence Knockdown/overexpression in cisplatin-resistant lung cells with IC50, ABC transporter, and WNT pathway readouts

    PMID:31579066

    Open questions at the time
    • Catalytic dependence and direct target genes unresolved
  16. 2020 Medium

    Placed RIOX2 in an upstream-downstream transcriptional axis: ZNF143 induces MDIG, which derepresses CDC6 via H3K9me3 removal.

    Evidence ChIP at MDIG and CDC6 promoters, gain/loss-of-function, and in vitro/in vivo tumor assays in HCC

    PMID:32312832

    Open questions at the time
    • Single-lab pathway placement
    • Direct CDC6 promoter binding not shown
  17. 2021 Medium

    Used genome-wide profiling to show RIOX2 controls host genes for viral entry through H3K9me3/H3K27me3 chromatin states.

    Evidence CRISPR-Cas9 KO with ChIP-seq and expression validation of NRP1/NRP2, cathepsins, glycan genes

    PMID:34335974

    Open questions at the time
    • Direct demethylase action vs indirect chromatin effects not distinguished
  18. 2022 High

    Defined an H3K36me3-dependent invasion program with a rescuable downstream effector (MAGED2).

    Evidence CRISPR KO with H3K36me3 ChIP-seq, RNA-seq, MAGED2 knockdown rescue, orthotopic xenograft, and migration assays in TNBC

    PMID:36124233

    Open questions at the time
    • Why X-linked loci are preferentially affected unexplained
  19. 2023 High

    Rigorously characterized RIOX2 as a substrate-selective histidine hydroxylase on Rpl27a, with defined inhibitory analogues.

    Evidence In vitro biochemistry with natural/unnatural histidine analogue peptides and inhibition assays

    PMID:36908702

    Open questions at the time
    • Cellular consequence of Rpl27a hydroxylation on translation unresolved
  20. 2023 High

    Established a physiological demethylase circuit in vivo: MDIG erases H3K9me3 at OTX2 to drive an OTX2–Myc loop sustaining liver regeneration.

    Evidence Liver-specific KO mice, hepatectomy/CCl4 injury, ChIP, ATAC-seq, OTX2 ChIP at Myc, and RNA-seq

    PMID:37709738

    Open questions at the time
    • Whether the same loop operates in non-hepatic tissues untested
  21. 2024 High

    Expanded the substrate repertoire to arginine methylation: RIOX2 is a bona fide H4R3me2a eraser important for neural stem cell programs and cognition.

    Evidence Photoaffinity capture, in vitro and cellular demethylation, molecular dynamics, and NSC-specific conditional KO with cognitive testing

    PMID:39587091

    Open questions at the time
    • Genome-wide H4R3me2a targets not fully mapped
  22. 2025 High

    Identified a non-histone arginine demethylase substrate, p53 R337me2a, linking RIOX2 catalysis directly to tumor-suppressor inactivation.

    Evidence In vitro demethylation, MS validation, oligomerization co-IP, target-promoter ChIP, and xenograft/spontaneous tumor models

    PMID:39864061

    Open questions at the time
    • Crosstalk between p53 demethylation and histone activities unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How RIOX2 selects among its multiple chemistries (H3K9me3, H3K36me3, H4R3me2a, p53 R337me2a demethylation, and Rpl27a hydroxylation) and is targeted to specific substrates and loci in a given context remains unresolved.
  • No structural model integrating substrate selectivity
  • Recruitment/targeting mechanism to specific promoters unknown
  • Relative contribution of catalytic vs scaffolding functions unquantified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140098 catalytic activity, acting on RNA 5 GO:0016491 oxidoreductase activity 4 GO:0140110 transcription regulator activity 3 GO:0140096 catalytic activity, acting on a protein 1
Localization
GO:0005634 nucleus 3 GO:0005730 nucleolus 2
Pathway
R-HSA-4839726 Chromatin organization 5 R-HSA-1640170 Cell Cycle 3 R-HSA-74160 Gene expression (Transcription) 3
Partners
CBX8JAK1MYCPRMT5RBBP4XRCC5XRCC6

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 mina53 (RIOX2) is a direct transcriptional target of c-Myc: c-Myc protein binds the mina53 promoter E-box sites in vivo, and ectopic c-Myc (but not a transactivation-domain mutant) induces mina53 mRNA even in the presence of protein synthesis inhibitors. RNAi knockdown of mina53 severely suppresses cell proliferation. Chromatin immunoprecipitation (ChIP) of c-Myc at mina53 promoter; promoter-reporter assays; c-MycER activation with cycloheximide; RNA interference with proliferation readout The Journal of biological chemistry High 12091391
2005 NO52 (RIOX2) localizes constitutively to the granular component of nucleoli, is present in free preribosomal particles but absent from cytoplasmic ribosomes, and co-immunoprecipitates with ribosomal proteins and non-ribosomal nucleolar proteins. Its nucleolar accumulation depends on ongoing rRNA transcription and the metabolic state of the cell. Immunolocalization; subcellular fractionation; co-immunoprecipitation followed by MALDI-MS; treatment with RNase A, actinomycin D, and serum starvation European journal of cell biology High 15819408
2009 mdig (RIOX2) demethylates tri-methyl lysine 9 of histone H3 (H3K9me3): overexpression reduces H3K9me3 at the rRNA gene promoter and increases RNA Pol I occupancy and rRNA transcription, while gene silencing has the opposite effect. Gene overexpression and siRNA knockdown; chromatin immunoprecipitation (ChIP) for H3K9me3 and RNA Pol I; rRNA expression assays Cell cycle (Georgetown, Tex.) Medium 19502796
2013 mdig (RIOX2) demethylates H3K9me3 at the promoter of the imprinted H19 lncRNA gene: overexpression reduces H3K9me3 at the H19 promoter and activates H19 transcription; shRNA/siRNA knockdown increases H3K9me3 and reduces H19 expression. In vitro demethylation assay with immunoprecipitated mdig and an H3K9me3 peptide confirmed catalytic activity. Overexpression and shRNA/siRNA knockdown with ChIP for H3K9me3; in vitro demethylation assay using immunoprecipitated mdig protein and histone H3 peptide substrate Oncotarget Medium 23965803
2013 Mina53-deficient mice show reduced Th17 cell infiltration into airways and increased Treg cell infiltration following allergen (house dust mite) challenge, with lower IL-4 and IL-5 levels, demonstrating that Mina53 (RIOX2) regulates the Th17/Treg balance and allergic airway responses. Mina53-knockout mouse model; intranasal allergen challenge; bronchoalveolar lavage cell differential counts; ELISA for cytokines; airway hyperresponsiveness measurement Cell structure and function Medium 23748603
2015 mdig (RIOX2) protein co-immunoprecipitates with DNA double-strand break repair and chromatin-binding proteins XRCC5, XRCC6, RBBP4, CBX8, PRMT5, and TDRD in lung cancer (A549) and bronchial epithelial (BEAS-2B) cells, validated by reciprocal co-immunoprecipitation. Co-immunoprecipitation with anti-mdig antibody followed by nanoESI-MS/MS proteomics (Orbitrap); reciprocal co-IP validation; four independent experiments Oncotarget Medium 26293673
2015 mdig (RIOX2) regulates cell cycle progression through p27(KIP1): knockdown of mdig increases p27(KIP1) mRNA and protein and inhibits phosphorylation of p27 at Thr187, causing cell cycle arrest; in human lung cancer tissues, mdig upregulation inversely correlates with p27(KIP1) levels. siRNA knockdown in A549 cells; MTT proliferation assay; cell cycle analysis; RT-qPCR for cell cycle regulators; Western blot for p27(KIP1) and phospho-p27(KIP1) isoforms; Western blot on human lung cancer tissue samples Tumour biology Medium 25851349
2016 mdig (RIOX2) directly interacts with c-Myc and JAK1 in multiple myeloma cell lines, contributing to hyperactivation of the IL-6-JAK-STAT3 signaling pathway; genetic silencing of mdig reduces activity of downstream effectors in this pathway. Co-immunoprecipitation; integrative genomics and proteomics; siRNA knockdown with pathway activity readouts (Western blot for STAT3 phosphorylation) Scientific reports Medium 27833099
2017 MDIG (RIOX2) regulates H3K9me3 at the p21(CIP1/WAF1) promoter in hepatocellular carcinoma: MDIG overexpression reduces H3K9me3 and activates p21 expression; knockdown has the opposite effect, influencing HCC cell proliferation and migration. Gain- and loss-of-function experiments (overexpression and siRNA knockdown) in HCC cells; ChIP for H3K9me3; Western blot for p21; xenograft tumor model Cell death & disease Medium 28471446
2018 MINA53 (RIOX2) regulates expression of the CDC45-MCM-GINS (CMG) complex genes required for DNA replication initiation; knockdown reduces CMG gene expression, induces DNA replication stress, diminishes ATM/ATR-H2AX DNA damage response, and leads to glioblastoma cell apoptosis. siRNA knockdown in glioblastoma cells; DNA replication initiation assays; RT-qPCR and Western blot for CMG genes; flow cytometry for apoptosis; Western blot for ATM/ATR-H2AX pathway components Cell death & disease Medium 30333481
2019 MINA53 (RIOX2) preferentially demethylates H3K36me3 in vitro, and its depletion by RNAi increases local H3K36me3 levels at the HIV-1 LTR, promoting HIV-1 latency reversal. The pan-JmjC inhibitor JIB-04 inhibits MINA53-mediated H3K36me3 demethylation and synergizes with latency-reversing agents to reactivate latent HIV-1. CRISPR/Cas9 screen; RNAi depletion; in vitro histone demethylation assay; ChIP for H3K36me3 at LTR; HIV-1 latency reactivation assays; JIB-04 inhibitor treatment Nucleic acids research High 31165872
2018 Loss of mdig (RIOX2) expression enhances global DNA methylation and H3K9me3 heterochromatin, and increases migration and invasion of triple-negative breast cancer cells, indicating mdig acts as an inhibitor of DNA and histone methylation and suppresses metastatic behavior in advanced breast cancer. siRNA/shRNA knockdown; global DNA methylation assay; chromatin accessibility assay; ChIP for H3K9me3; Transwell migration/invasion assays Signal transduction and targeted therapy Medium 30254753
2020 ZNF143 promotes expression of MDIG (RIOX2) by direct transcriptional activation; MDIG in turn reduces H3K9me3 at the CDC6 promoter to activate CDC6 transcription and accelerate HCC cell-cycle progression, establishing a ZNF143-MDIG-CDC6 oncoprotein axis. ChIP for ZNF143 at MDIG promoter; gain- and loss-of-function experiments; ChIP for H3K9me3 at CDC6 promoter; Western blot; in vitro and in vivo tumor growth assays Cancer research Medium 32312832
2018 Phylogenetic and structural analyses show that RIOX2 (MINA53) and RIOX1 (NO66) share conserved active-site residues within their JmjC domains, a dimerization domain, and a winged-helix domain; the proteins catalyze C-3 histidine hydroxylation in ribosomal proteins (Rpl27a for MINA53). RIOX2 has a distinct subnuclear localization in Hydra compared to human, indicating evolutionary adaptation. Phylogenomic analysis of 49 metazoan species; domain architecture comparison; immunofluorescence for subnuclear localization in HeLa cells and Hydra BMC evolutionary biology Medium 29914368
2023 MINA53 (RIOX2) is a histidine hydroxylase with narrow substrate selectivity: it catalyzes C-3 hydroxylation of a histidine residue in ribosomal protein Rpl27a. Inhibition assays with histidine analogues in Rpl peptides showed that MINA53 activity can be inhibited by competition with non-oxidized peptides containing acyclic side-chain analogues (Asn, Gln, homoGln). In vitro biochemical assays with natural and unnatural histidine analogues incorporated into Rpl peptides; substrate selectivity assays; inhibition assays RSC chemical biology High 36908702
2023 MDIG (RIOX2) demethylates H3K9me3 at the OTX2 promoter to increase chromatin accessibility, allowing OTX2 transcription factor expression; OTX2 then binds the Myc promoter to activate Myc expression, forming a positive feedback loop that sustains hepatocyte proliferation during liver regeneration. Liver-specific MDIG knockout mice; partial hepatectomy and CCl4 injury models; ChIP for H3K9me3 at OTX2 promoter; ATAC-seq for chromatin accessibility; ChIP for OTX2 at Myc promoter; RNA-seq Signal transduction and targeted therapy High 37709738
2024 Mina53 (RIOX2) is a bona fide H4R3me2a (asymmetric di-methylation at arginine 3 of histone H4) eraser: identified as an H4R3me2a interactor by photoaffinity capture, it demethylates H4R3me2a in vitro and in cells. In a transgenic mouse with neural stem/progenitor cell-specific Mina53 deletion, failure to demethylate H4R3me2a dysregulates genes for NSC proliferation and differentiation, impairing cognitive function. Photoaffinity capture for interactor identification; in vitro demethylation biochemical assay; cellular H4R3me2a quantification; molecular dynamics simulation; transgenic conditional KO mouse with cognitive testing Nature communications High 39587091
2025 Mina53 (RIOX2) is an arginine demethylase that removes asymmetric dimethylation at arginine 337 of p53 (p53 R337me2a): demethylation reduces p53 protein stability and oligomerization, alters chromatin modifications at p53 target gene promoters, and suppresses p53-mediated transcriptional activation and cell-cycle arrest, thereby promoting tumor growth in mouse xenograft and spontaneous tumor models. In vitro demethylation assay; mass spectrometry for p53 arginine methylation status; co-immunoprecipitation for oligomerization; ChIP for chromatin modifications at p53 target promoters; xenograft and spontaneous tumor mouse models; loss-of-function experiments Cell reports High 39864061
2017 mdig (RIOX2) suppresses epithelial-mesenchymal transition (EMT) in NSCLC by inhibiting GSK-3β phosphorylation, which promotes β-catenin phosphorylation and destabilization, downregulating slug, snail, and ZEB1 transcription factors, thereby increasing epithelial markers (E-cadherin, claudin-1) and decreasing mesenchymal markers (vimentin, N-cadherin). Lentiviral overexpression and knockdown in A549 and HUVEC cells; Transwell invasion/migration assays; Western blot for GSK-3β, β-catenin, EMT markers and transcription factors International journal of oncology Medium 29039479
2019 MDIG (RIOX2) promotes cisplatin resistance in lung adenocarcinoma by activating WNT/β-catenin signaling, which upregulates ABC transporter expression (ABCB1, ABCC1, ABCG2); overexpression increases IC50 for cisplatin while knockdown reduces it. siRNA knockdown and overexpression in A549 and A549/DDP cisplatin-resistant cells; RT-qPCR and Western blot for MDIG, ABC transporters, WNT pathway components; IC50 determination Oncology letters Medium 31579066
2021 mdig (RIOX2) depletion by CRISPR-Cas9 in bronchial epithelial cells reduces expression of SARS-CoV-2 receptors NRP1 and NRP2, cathepsins, and glycan metabolism genes, associated with enrichment of H3K9me3 and/or H3K27me3 at these loci as determined by ChIP-seq. CRISPR-Cas9 gene editing; ChIP-seq for H3K9me3/H3K27me3; RT-qPCR and Western blot for NRP1, NRP2, cathepsins; gene ontology analysis Theranostics Medium 34335974
2022 Mdig (RIOX2) deletion in triple-negative breast cancer MDA-MB-231 cells enhances global H3K36me3 and upregulates X-chromosome-linked genes for cell motility and invasion (including MAGED2); silencing MAGED2 partially reverses the invasive migration of mdig-KO cells, establishing H3K36me3/MAGED2 as a downstream effector axis. CRISPR-Cas9 mdig knockout; ChIP-seq for H3K36me3; RNA-seq; siRNA knockdown of MAGED2; in vivo orthotopic xenograft; Transwell migration assay iScience High 36124233

Source papers

Stage 0 corpus · 46 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 A novel myc target gene, mina53, that is involved in cell proliferation. The Journal of biological chemistry 98 12091391
2009 Lung cancer-associated JmjC domain protein mdig suppresses formation of tri-methyl lysine 9 of histone H3. Cell cycle (Georgetown, Tex.) 79 19502796
2013 Mdig de-represses H19 large intergenic non-coding RNA (lincRNA) by down-regulating H3K9me3 and heterochromatin. Oncotarget 78 23965803
2005 The Human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer. Oncogene 65 15897898
2004 Increased expression of a Myc target gene Mina53 in human colon cancer. The American journal of pathology 62 14695334
2019 A CRISPR/Cas9 screen identifies the histone demethylase MINA53 as a novel HIV-1 latency-promoting gene (LPG). Nucleic acids research 50 31165872
2020 ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma. Cancer research 48 32312832
2007 Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma. Pathology international 47 17803656
2017 Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity. Cell death & disease 43 28471446
2014 Carcinogenic metalloid arsenic induces expression of mdig oncogene through JNK and STAT3 activation. Cancer letters 43 24434654
2005 Protein NO52--a constitutive nucleolar component sharing high sequence homologies to protein NO66. European journal of cell biology 41 15819408
2015 Oncoprotein mdig contributes to silica-induced pulmonary fibrosis by altering balance between Th17 and Treg T cells. Oncotarget 37 25669985
2007 Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma. Journal of pediatric surgery 37 18022432
2007 Expression of Myc target gene mina53 in subtypes of human lymphoma. Oncology reports 32 17786344
2018 Loss of mdig expression enhances DNA and histone methylation and metastasis of aggressive breast cancer. Signal transduction and targeted therapy 31 30254753
2009 Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells. Journal of cancer research and clinical oncology 30 19756735
2010 Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology 28 20070393
2018 MINA53 deficiency leads to glioblastoma cell apoptosis via inducing DNA replication stress and diminishing DNA damage response. Cell death & disease 25 30333481
2012 Upregulated expression of Mina53 in cholangiocarcinoma and its clinical significance. Oncology letters 24 22783387
2006 Immunohistochemical expression of Mina53 and Ki67 proteins in human primary gingival squamous cell carcinoma. The Kurume medical journal 24 17317935
2006 Expression of Mina53, a product of a Myc target gene in mouse testis. International journal of andrology 22 16533354
2019 New discoveries of mdig in the epigenetic regulation of cancers. Seminars in cancer biology 21 31276784
2013 Ablation of Mina53 in mice reduces allergic response in the airways. Cell structure and function 20 23748603
2008 Expression of Mina53 and its significance in gastric carcinoma. The International journal of biological markers 20 18629780
2016 Proteomic Characterization of the World Trade Center dust-activated mdig and c-myc signaling circuit linked to multiple myeloma. Scientific reports 19 27833099
2021 Cooperation between NRF2-mediated transcription and MDIG-dependent epigenetic modifications in arsenic-induced carcinogenesis and cancer stem cells. Seminars in cancer biology 18 33823236
2019 MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT/β-catenin signaling pathway. Oncology letters 17 31579066
2015 Current understanding of mdig/MINA in human cancers. Genes & cancer 17 26413213
2015 The proteomic investigation reveals interaction of mdig protein with the machinery of DNA double-strand break repair. Oncotarget 14 26293673
2014 Potential effects of Mina53 on tumor growth in human pancreatic cancer. Cell biochemistry and biophysics 13 24522517
2023 MDIG-mediated H3K9me3 demethylation upregulates Myc by activating OTX2 and facilitates liver regeneration. Signal transduction and targeted therapy 12 37709738
2021 The mineral dust-induced gene, mdig, regulates angiogenesis and lymphangiogenesis in lung adenocarcinoma by modulating the expression of VEGF-A/C/D via EGFR and HIF-1α signaling. Oncology reports 12 33760153
2020 Molecular Signatures of JMJD10/MINA53 in Gastric Cancer. Cancers 12 32370161
2017 Mdig suppresses epithelial-mesenchymal transition and inhibits the invasion and metastasis of non‑small cell lung cancer via regulating GSK-3β/β-catenin signaling. International journal of oncology 11 29039479
2021 Environmentally-induced mdig contributes to the severity of COVID-19 through fostering expression of SARS-CoV-2 receptor NRPs and glycan metabolism. Theranostics 10 34335974
2022 Deletion of mdig enhances H3K36me3 and metastatic potential of the triple negative breast cancer cells. iScience 8 36124233
2018 Phylogenetic and genomic analyses of the ribosomal oxygenases Riox1 (No66) and Riox2 (Mina53) provide new insights into their evolution. BMC evolutionary biology 8 29914368
2023 Jumonji domain-containing protein RIOX2 is overexpressed and associated with worse survival outcomes in prostate cancers. Frontiers in oncology 6 36776320
2024 Mina53 demethylates histone H4 arginine 3 asymmetric dimethylation to regulate neural stem/progenitor cell identity. Nature communications 5 39587091
2023 Substrate selectivity and inhibition of histidine JmjC hydroxylases MINA53 and NO66. RSC chemical biology 5 36908702
2015 Mdig, a lung cancer-associated gene, regulates cell cycle progression through p27(KIP1). Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 5 25851349
2023 MicroRNA-140-3p inhibits proliferation and promotes apoptosis in non-small cell lung cancer by targeting MDIG. Environmental toxicology 4 38009637
2018 Effects of mdig on proliferation and apoptosis of lung cancer cells. Oncology letters 2 30546450
2025 Mina53 catalyzes arginine demethylation of p53 to promote tumor growth. Cell reports 1 39864061
2022 Depletion of Mdig Changes Proteomic Profiling in Triple Negative Breast Cancer Cells. Biomedicines 1 36009568
2024 MDIG in Breast Cancer Progression and Metastasis. Advances in experimental medicine and biology 0 39586990

Missed literature

Know a paper Affinage missed for RIOX2? Flag it for the maintainers and the community.

No submissions yet.